Downloadable resources

About treating patients with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) with CABLIVI for easy reference

CABLIVI (caplacizumab-yhdp) Dosing Guide thumbnail

CABLIVI Dosing Guide

Important information for you and your patients regarding the CABLIVI dosing schedule.

CABLIVI (caplacizumab-yhdp) Patient Enrollment Form thumbnail

CABLIVI Patient Enrollment Form

Enroll patients in CABLIVI Patient Solutions for access to specialty pharmacy services, financial assistance, and supplemental training.

CABLIVI (caplacizumab-yhdp) Patient Solutions thumbnail

CABLIVI Patient Solutions

Learn more about the support offered through CABLIVI Patient Solutions.

CABLIVI (caplacizumab-yhdp) Billing and Coding Guide thumbnail

CABLIVI Billing and Coding Guide

Find more information regarding coverage and other reimbursement considerations.

CABLIVI (caplacizumab-yhdp) Hospital Guide thumbnail

CABLIVI Hospital Guide

This guide highlights key information related to the procurement of, and patient access to, CABLIVI.

CABLIVI (caplacizumab-yhdp) Cost Flashcard thumbnail

CABLIVI Cost Flashcard

Learn more about the costs of CABLIVI for the hospital vs costs covered by third-party insurance or patients.

Day 1 icon

Choose CABLIVI on day 1 in combination with PEX and immunosuppressive therapy

Guidelines checkmarks

ISTH Guideline recommendations*

Who should not start CABLIVI?

  • CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients
  • Withhold CABLIVI treatment 7 days prior to elective surgery, dental procedures, or other invasive interventions

*A conditional recommendation defined as desirable effects of the recommendation probably outweighing the undesirable effects. Assumes timely access to ADAMTS13 testing and clinical diagnosis based on high likelihood of aTTP/iTTP. In de novo patients where no reasonable access to ADAMTS13 activity testing is available, the Guidelines do not recommend CABLIVI; however, treatment of a patient previously diagnosed with aTTP/iTTP could be safely undertaken on clinical grounds without the need for a confirmatory ADAMTS13 test.1

ADAMTS13=a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13; ISTH=International Society on Thrombosis and Haemostasis; PEX=plasma exchange.